This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The epidemiological features of prostatic carcinoma are:

  • incidence of prostate cancer varies widely among populations worldwide
    • a low incidence is usually seen in Asian men while a higher incidence is observed in northern European countries
    • however the highest incidence is reported from African American men (1)

  • in Europe the incidence rate is 214 cases per 1000 men (2)

  • in the UK, it is the most common cancer and the second most common cause of death from cancer in adult males (2)
    • it is responsible for around 25% of the new diagnoses of malignant cancer in men in England and Wales
    • prostate cancer is the most common cancer in men, and the second most common cancer in the UK
      • in 2014, there were over 46,000 new diagnoses of prostate cancer, which accounts for 13% of all new cancers diagnosed. About 1 in 8 men will get prostate cancer at some point in their life
      • prostate cancer can also affect transgender women, as the prostate is usually conserved after gender-confirming surgery, but it is not clear how common it is in this population
      • more than 50% of prostate cancer diagnoses in the UK each year are in men aged 70 years and over (2012), and the incidence rate is highest in men aged 90 years and over (2012 to 2014)
      • out of every 10 prostate cancer cases, 4 are only diagnosed at a late stage in England (2014) and Northern Ireland (2010 to 2014)
      • total of 84% of men aged 60 to 69 years at diagnosis in 2010/2011 are predicted to survive for 10 or more years after diagnosis. When diagnosed at the earliest stage, virtually all people with prostate cancer survive 5 years or more: this is compared with less than a third of people surviving 5 years or more when diagnosed at the latest stage.

Prostate cancer is mainly a disease of older men:

  • average age at diagnosis is 70 -74 years and the average age at mortality is 80-84 years
  • rare before 50 years but after that the incidence increases steeply with age e.g.- age 55-59 the incidence rate is 155 per 100,000 men, in 65-69 it is 510 per 100,000, and by 75-79 the rate is 751 per 100,000.
  • is the most common malignant condition in men over 65 years

50-60% of cases present with metastatic disease:

  • vast majority are well differentiated adenocarcinomas (4)
  • early, potentially curable, prostate cancers are either impalpable or have only a small nodule and a PSA that is usually less than 15 ng/ml (1)

Patients at higher risk of developing prostate cancer include:

  • patients with a first degree relative with prostate or breast cancer
  • there is probably also an increased risk of prostate cancer in Afro-Carribeans - there is a 3 fold increase in the incidence of the disease in black men compared to white men (regardless of the country of origin of the black man) (3)
  • in the UK, a man's lifetime risk of being diagnosed with prostate cancer is 1 in 8 (6)
    • study evidence revealed that:
      • lifetime risk of being diagnosed with prostate cancer is approximately 1 in 8 for White men, 1 in 4 for Black men, and 1 in 13 for Asian men, whereas that of dying from prostate cancer is approximately 1 in 24 for White men, 1 in 12 for Black men, and 1 in 44 for Asian men

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.